...Good afternoon. Welcome, everybody, to the 2024 Annual Shareholders Meeting corporate update for Ionis Pharmaceuticals. My name is Brett Monia, I'm the Chief Executive Officer of Ionis, and I'm thrilled to provide an update on the remarkable progress we're making at Ionis today. These are my forward-looking statements that I recommend to you at your convenience. So at Ionis, we are executing on a clear, clear vision to drive substantial value for shareholders for all stakeholders. And that vision is to substantially extend the leadership position that we created in RNA targeted therapeutics and we're doing so phases by focusing on three specific and highly important investment areas first is to extend and diversify our technology for oligonucleotide therapeutics. Second is to prioritize and expand the Ionis wholly owned pipeline, and thirdly, to deliver Ionis medicines from our wholly owned pipeline directly to patients commercialization while supporting our partnered pipeline. All of this...
